anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will complete the baseline session, a 1:1 motivation building session, and 8 weeks of ACT group therapy. They will then complete a final study visit and a follow-up study visit to occur 6 month after the end of therapy.
Health conditions requiring antithrombotic therapy are highly prevalent in Canada, contributing substantially to healthcare costs and patient quality of life. For example, over 60,000 Canadians will experience a heart attack per year.1 Alarming statistics such as this warrant appropriate treatment approaches from clinicians who specialize in cardiovascular conditions. The CCC is a national conference during which individuals with an interest or expertise in cardiovascular health from across the country attend. Leveraging this unique opportunity by implementing a simple educational endeavour during the 2023 event can provide instrumental insights on the most appropriate treatments recommended from the latest clinical practice guidelines to a wide set of practitioners; this could, in turn, potentially improve patient health outcomes.

This endeavour will take place at a set date from October 25th to 29th, 2023. Attendees of the CCC who approach a booth set up by the lead investigator of this project will be presented with the study letter of information and consent form on a tablet (i.e., an iPad). After providing an electronic informed consent to participate, a series of patient case scenarios that require antithrombotic care and therapy will be shown. For each case scenario, the attendee (now, considered a study participant) will be asked to indicate the treatment approach that he/she would choose. And finally, after reviewing all case scenarios and selecting the best treatment approach to his/her knowledge, the participant will be asked to provide an email address (which could be an anonymized one) to send the most appropriate treatment approaches for each case scenario. This last step allows the participant an educational opportunity to learn what the best practice approach is based on the most up-to-date clinical practice guidelines. The approximate total duration of the study is one-hour in total.
The invention provides an iota-carrageenan degrading bacterium as well as a fermentation method and an application thereof, and relates to cytophaga bacteria. The collection number of the iota-carrageenan degrading bacterium (Cellulophaga sp.) KL-A is CGMCC No. 8694. A production method of iota-carrageenan hydrolytic enzyme comprises the following steps: coating an iota-carrageenan solid medium with the activated iota-carrageenan degrading bacterium (Cellulophaga sp.) KL-A, picking and inoculating a single colony into a seed medium and culturing so as to obtain a seed solution; and inoculating the seed solution into fermentation liquid according to 1%-5% of inoculation quantity, and carrying out shake cultivation so as to obtain fermented supernatant; and carrying out salt fractionation by using ammonium sulfate and DEAE (diethyl-aminoethanol)-cellulose chromatography on the obtained fermented supernatant at the temperature of 4 DEG C, dialyzing so as to remove salt, and carrying out vacuum freeze drying so as to obtain the iota-carrageenan hydrolytic enzyme. Iota-carrageenan oligosaccharides can be applied in the preparation of antibacterial agents, antiviral drugs, immunomodulators, antioxidants and the like.
ESTRING® (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days. ESTRING has the following dimensions: outer diameter 55 mm; cross-sectional diameter 9 mm; core diameter 2 mm. One ESTRING should be inserted into the upper third of the vaginal vault, to be worn continuously for three months.

Estradiol is chemically described as estra-1,3,5(10)-triene-3,17β-diol. The molecular formula of estradiol is C18H24O2 and the structural formula is:

The molecular weight of estradiol is 272.39.
BACKGROUND: Unstable fractures of the distal radius fractures (DRFs) may result in malunion, usually consisting of subsequent shortening and angular deviations. Ulnar shortening osteotomy (USO) is assumed to be a simpler procedure than radial correction osteotomy, resulting in fewer complications and comparable outcomes. The aim of this study was to identify the best surgical technique to perform USO to restore distal radioulnar joint congruency after DRF malunion.
METHODS: A systematic review of the literature is performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines in February 2022 to identify studies reporting outcomes and surgical technique for isolated USO. The primary outcome was complication rates. Secondary outcomes included functional, radiologic, and patient-rated outcomes. The methodological index for nonrandomized studies criteria were used to assess the quality of evidence.
RESULTS: Included were 12 cohorts (185 participants). Due to substantial heterogeneity, a meta-analysis could not be performed. The overall complication rate was 33% (95% confidence interval, 16% to 51%). The most reported complication was implant irritation (22%), often requiring removal of the implant (13%). Only 3% nonunions were mentioned. Functional and patient-rated outcomes improved in most patients after USO. Quality of evidence of the papers was low to very low. Common methodological flaws were related to retrospective research.
CONCLUSION: No evident differences in complication rates and functional outcomes between the surgical techniques were observed. Based on this literature, most complications are related to implant irritation. Nonunion and infection rates were rare. Therefore, a surgical technique with a buried implant might be preferred. This hypothesis requires further investigation.
Clinical studies of doxepin hydrochloride cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

The extent of renal excretion of doxepin has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections.

Sedating drugs may cause confusion and oversedation in the elderly; elderly patients generally should be observed closely for confusion and oversedation when started on doxepin hydrochloride cream (see WARNINGS). An 80-year old male nursing home patient developed probable systemic anticholinergic toxicity which included urinary retention and delirium after doxepin hydrochloride cream had been applied to his arms, legs and back three times daily for two days.
A system for providing medical information to a patient is provided. The system includes a medical information server, including a software engine, coupled to a memory location. The memory location stores a plurality of voice mailboxes. A voice mailbox includes at least two segments. A first segment for test results, or an upload-source note, and a second segment for account owner information, or a chart note. An upload-source, such as a testing facility or laboratory, is coupled to the server and provides test results to the mailbox. An interactive voice response (IVR) software interface is also coupled to the engine. The IVR provides the medical information in the mailbox responsive to a user input. The system may also include a patient database. Further, the engine generates alerts to the account owner based upon particular events. The system is also configured to prevent conflicting accesses by users. The system is convenient to use due to reporting features and an identifier function used to locate particular voice mailboxes.
Described herein are methods to enhance protein secretion in a host cell. In preferred embodiment, the host cell is a gram-positive microorganism such as a  Bacillus . In another preferred embodiment, the host cell is a gram-negative microorganism. Preferably the gram-negative microorganism is an  Escherichia coli  or a member of the genus  Pantoea . Protein secretion may be enhanced by the overexpression of protein components of the Tat pathway. Alternatively, secretion of foreign proteins can be selectively enhanced by forming a chimeric polypeptide comprising a tat signal sequence and the protein of interest. In a preferred embodiment, the tat signal sequence is selected from phoD or LipA.
A superior phosphatide emulsifier especially suited for use in parenteral preparations is obtained by preparing a solution containing the alcohol-soluble fraction of commercial lecithin, treating said solution with from 1 to 20 parts by weight of a basic calcium compound, e.g. calcium hydroxide or calcium acetate, per part of the alcohol-soluble fraction of commercial lecithin to form an insoluble salt with the phosphatidic acid fraction and removing the insoluble salt and the solvent to obtain the emulsifier. The solution which is treated may suitably be an alcohol solution containing 1 part by weight per 100 parts by weight of the alcohol-soluble fraction of commercial soya lecithin, which solution may be obtained by extracting commercial soya lecithin with several volumes of a lower aliphatic alcohol, e.g. methanol, ethanol, propanol, isopropanol or butanol, and removing the solvent.  The product is stated to contain a high percentage of phosphatidyl choline and phosphatidyl ethanolamine as compared with the known alcohol-soluble fractions.  The phosphatide product is suitable for use as an emulsifier in a parenteral fat emulsion and is stated to be devoid of vazo depressor effects. A specified emulsion contains 1% by weight triolein and 0.8% by weight of the phosphatide.
BACKGROUND: There are no reliable methods in clinical practice to diagnose adrenal insufficiency (AI) in patients with cirrhosis owing to variable cortisol-binding protein levels. This leads to unreliable results in ACTH stimulated serum cortisol test. We aimed to estimate the long-acting porcine (LA)ACTH-stimulated serum and salivary cortisol levels of patients at different stages of cirrhosis using second generation electrochemiluminescence and to determine the prevalence of true adrenal insufficiency in these patients.
DESIGN, PATIENTS AND MEASUREMENTS: We included 135 noncritical patients with cirrhosis (45 each from CHILD A, B and C) and 45 healthy controls. Serum and salivary samples were collected at baseline in the morning and at 1 and 2 h after LA-ACTH injection.
RESULTS: In healthy subjects, the 2.5th centile of 2 h ACTH stimulated serum and salivary cortisol were 19.8 and 0.97 μg/dL, which were used as cut-offs for defining AI based on serum and saliva respectively. The median (interquartile-range) 2-h stimulated salivary cortisol in Child A, B, C categories and controls were 1.36(1.23-2.38), 1.46(1.18-2.22), 1.72(1.2-2.2) and 2.12(1.42-2.72) μg/dL respectively. Six subjects (4.4%) were diagnosed to have AI based on stimulated salivary cortisol cut-off, whereas 39 (28.9%) cirrhosis subjects had inadequately stimulated serum cortisol. Three patients (symptomatic) required steroid replacement therapy. Hypoalbuminemia was identified as a major risk factor for the misdiagnosis of adrenal insufficiency by serum cortisol-based testing.
CONCLUSIONS: Long-acting porcine ACTH stimulated salivary cortisol reduces the overdiagnosis of adrenal insufficiency compared to serum cortisol in cirrhosis liver. Stimulated salivary cortisol is a promising investigation for evaluation of adrenal function in cirrhosis and more studies are required for its further validation before clinical use.
Powdered laundry detergents, encompassing a diverse blend of organic and inorganic compounds, are crucial in efficiently removing dirt in household cleaning. This study investigated the cytotoxic and genotoxic potential of commonly used powdered laundry detergents in Sri Lanka using the Allium cepa bioassay. Five detergents (four branded A, B, C, and D, and one non-branded E) were selected for assessment. Toxicity evaluations were conducted across a range of predetermined aqueous detergent concentrations (0-2500 mg/L) using the A. cepa bioassay, with all experiments being triplicated and following standard protocols. Exposure to detergent concentrations up to 500 mg/L resulted in mitosis suppression, nuclear aberrations, and chromosomal abnormalities in A. cepa, indicating concentration-dependent cytotoxicity and genotoxicity. Condensed nuclei were notably prevalent among nuclear abnormalities, while vagrant chromosomes and chromosomal adherence were the most frequent chromosomal aberrations observed. At higher concentrations (> 500 mg/L), the selected detergents induced necrotic cell death in A. cepa root meristematic cells. This study warns to avoid the unnecessary use of detergents as they cause significant ecological risks and advocates for further research to comprehensively assess detergent toxicity across diverse organisms within ecosystems to safeguard ecosystem health effectively.
The original painDETECT questionnaire (PDQ) DANBIO study was a survey among all DANBIO users having an arthritis diagnosis 'Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey'. The PDQ was implemented onto the DANBIO touch screens for a period of 6 months in 2013-14 and data from more than 7000 individual patients were collected. The overall background for the study was that central pain mechanisms may be prominent in subsets of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and other spondyloarthritis (SpA). The study showed that approximately 50 % of patients experienced significant pain levels and that a high PDQ score was associated with higher levels of pain and DAS28 but not with markers of inflammatory activity such as CRP and swollen joint count. Furthermore, indications of more frequent bio-switch in the PDQ groups showing neuropathic pain features were found.

The aim of this study is to examine the association between drug retention of biological DMARDs (bDMARDs) and the PDQ pain classification categories (i.e. non-neuropathic vs. neuropathic features) and to investigate whether this categorization is predictive of drug retention and changes in clinical outcomes over a 5-year period.
The surgical procedure began with creating the scleral flap and conjunctiva in the usual manner. The sub flap tissue was then rinsed with balanced saline, and a piece of tissue measuring 1.5mm x 2mm was excised from the inferior trabecular tissue of the scleral flap. Next, peripheral iris excision was performed in the corresponding position and the iris was rinsed to remove pigment in the vicinity of the incision. To control the tension of the sutures, the amniotic membrane was placed under the scleral flap, followed by meticulous suturing of the conjunctival flap.
Participants randomized to the intervention arm will undergo a substance use screening and brief intervention delivered by the peer-mentors. Screening will be performed using the ASSIST-Y (28). The brief intervention will be delivered in a single session (20-30 minutes) using the FRAMES model i.e.(i) providing feedback on screening results (ii) ensuring responsibility on the part of the adolescents (iii) giving clear advice to stop/cut down (iv) giving menu of options (alternative healthy behaviors to engage in) (v) expressing empathy, and (vi) encouraging self-efficacy (15). The BI will be delivered for the highest scoring substance or the one the adolescent identifies as the most problematic.
TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
In treatment period subjects will receive once daily 100 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
The management of skin wound healing is still a challenge. MicroRNA-21 (miR-21) has been reported to play important roles in wound repair; however, the underlying mechanism needs to be further clarified. The present study aimed to study the direct role of miR-21 in skin wound healing in miR-21 KO mice and to investigate the role of miR-21 in controlling the migration and proliferation of primary human skin cells and its underlying mechanism(s). miR-21 KO and wild-type (WT) mice were used for in vivo wound healing assays, while mouse and human primary skin cells were used for in vitro assays. miR-21 inhibitors or mimics or negative control small RNAs were transfected to either inhibit or enhance miR-21 expression in the human primary dermal fibroblasts or epidermal cells. RNA sequencing analysis was performed to identify the potential molecular pathways involved. We found that the loss of miR-21 resulted in slower wound healing in miR-21 KO mouse skin and especially delayed the healing of dermal tissue. In vitro assays demonstrated that the reduced expression of miR-21 caused by its inhibitor inhibited the migration of human primary dermal fibroblasts, which could be enhanced by increased miR-21 expression caused by miR-21 mimics. RNA-sequence analysis revealed that the inhibition of miR-21 expression downregulated the inflammatory response pathways associated with the decreased expression of inflammatory cytokines, and the addition of IL-1β into the culture medium enhanced the migration and proliferation of dermal fibroblasts in vitro. In conclusion, miR-21 in dermal fibroblasts can promote the migration and growth of epidermal and dermal cells to enhance skin wound healing through controlling the expression of inflammatory cytokines.
Peritoneal dialysis (PD) is one of important way of renal replacement treatment worldwide. In China, about 40,000 patients suffered from end stage renal disease treated with PD, and almost of them followed continuous ambulatory peritoneal dialysis (CAPD) because of the expensive price of import automated PD (APD) machines although the higher clearance of solute, lower rate of PD related peritonitis and higher quality of life (QOL) in patients treated with APD compared those with CAPD. Now, cheaper domestic APD machines ( PDGO, Fuzhou, China) are accessed to the ESRD patients in china, but the efficacy and safety of which are not fully clear. This will be a prospective, randomized, controlled, multi-center study. Patients in treatment group will receive APD while those in control group will receive CAPD for 8 weeks. After followed-up for 8 weeks, the adequacy of PD, residual kidney function , peritoneum function and QOL of patients will be evaluated.
The purpose of this invention is to provide a teeth-cleaning mousse type toothpaste without grinding agent and having a slight-bubbling function, and manufacturing method thereof. The invented manufacturing method comprises the following steps: heating and mixing 0.4% mint menthol and 10 wt% of sodium lauroyl sarcosinate first, and then putting into a mixed liquid that contains 0.1% of methyl salicylate, and 0.05% of Eucalyptus extract, 0.1% mint extract, and 0.4% spearmint extract. After that, the mixture is put into pure water and mixed with other compositions and keep on stirring until the mixture is even. Then the mixture is added with oil and mixed and heated. After having been stirred in higher speed to make the mixture uniform, the mixture is cooled down and deaerated, and packed to finished product. The abovementioned other material include 1.8% of Na Saccgarin, 0.05wt% of sodium fluoride, 0.45% Xylitol, 0.05% of Sodium Benzoate, 0.5% of potassium nitrate and 2 % of alcohol.
Patients will discontinue the natalizumab therapy at once and initiate another disease modifying therapy at 1 month following the last natalizumab infusion. The disease modifying therapy at 1 month following natalizumab discontinuation will be at the discretion of the neurologist and may differ among patients.
A dome for applying a vacuum to a patient's breast is comprised of a generally rigid dome capable of withstanding a pressure differential, with a rim and rim cushion underlying the rim of the dome for supporting a rim from the patient's skin surface. The rim may be generally wider than the dome in order to distribute the attendant forces across a greater surface and avoid tissue damage. A sticky sole underlies the rim cushion and seals the rim cushion to the patient's skin to thereby preserve the vacuum within the dome. The sticky sole may be comprised of any adhesive material or even be achieved through the use of an appropriate material for the rim cushion itself. A portable pump unit is connected to the domes and maintains the vacuum within the domes during a recommended protocol. By using the device in accordance with the prescribed protocol, the growth of cancer cells and tumors within the breasts are inhibited.
OBJECTIVE: Early articular cartilage lesion (CL) is a vital sign in the onset of posttraumatic knee osteoarthritis (PTOA) in patients with anterior cruciate ligament deficiency (ACLD). Researchers have suggested that altered kinematics could accelerate CLs and, therefore, lead to the onset of PTOA. However, little is known about whether specific knee kinematics exist that lead to early CL in chronic ACLD knees. Level walking is the most frequent and relevant in vivo activity, which greatly impacts knee health. We hypothesized that the knee kinematics during level walking in chronic ACLD knees with early tibiofemoral CL would significantly differ from those of chronic ACLD knees without early tibiofemoral CL.
METHODS: Thirty patients with a chronic ACLD history, including 18 subjects with CLs and 12 subjects without CLs, and 35 healthy control subjects were recruited for the study from July 2020 to August 2022. The knee kinematic data during level walking were collected using a three-dimensional motion analysis system. The kinematic differences between groups were compared using statistical parametric mapping with one dimension for One-Way ANOVA. The cartilage statuses of the ACLD knees were assessed via MRI examination. The CLs distribution of subjects was evaluated using a modified Noyes scale and analyzed by chi-square tests.
RESULTS: ACLD knees with CLs had significantly greater posterior tibial translation (7.7-8.0mm, 12%-18% gait cycle GC, p = 0.014) compared to ACLD knees without CLs during level walking. ACLD knees with CLs had greater posterior tibial translation (4.6-5.5mm, 0%-23% GC, p < 0.001; 5.8-8.0mm, 86%-100% GC, p < 0.001) than healthy controls during level walking. In the group of ACLD knees with CLs, CL is mainly located in the back of the tibia plateau and front of load bearing area of the medial femoral condyle (p < 0.05).
CONCLUSION: Chronic anterior cruciate ligament deficient knees with cartilage lesions have increased posterior tibial translation compared to anterior cruciate ligament deficient knees without cartilage lesions and healthy subjects. The posterior tibial translation may play an important role in knee cartilage degeneration in ACLD knees. The increased posterior tibial translation and cartilage lesion characteristics may improve our understanding of the role of knee kinematics in cartilage degeneration and could be a helpful potential reference for anterior cruciate ligament deficient therapy, such as physical training to improve abnormal kinematic behavior.